Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.00 +1.63%

+$0.10 today

Market cap
$109.62M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 0.86M

Average 0.66M

Returns on capital

Upstream Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-42.2%

avg -4.1%

ROIC

-47.0%

avg -68.5%

ROA

-40.5%

avg -50.1%

Analysis

ROA is currently the strongest return metric at -40.5% versus its period average of -50.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

E. Rand Sutherland

Chief Executive Officer & DirectorUSD 1M56——

Aaron Deykin

Chief Medical Officer and Head of Research & DevelopmentUSD 741.8K5932.30K0.06%

Michael Paul Gray

Chief Financial Officer & Chief Operating OfficerUSD 706.3K55——

Allison Ambrose

Senior Vice President, General Counsel & SecretaryUSD 59.79K4115.56K0.03%

Fang Xie

Vice President & Head of Biometrics————

Lisa Fiering

Senior Vice President of People & Culture————

Mersedeh Miraliakbari

Senior Vice President of Regulatory Affairs & Quality————

Stacy Price

Chief Technology Officer—57——

Adam Houghton

Chief Business Officer—5522.90K0.04%

Meggan Buckwell

Director of Corporate Communications & Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

15

$104,796.49

Net Transaction Value

−$104,796.49

Net selling

Most Active

GRAY MICHAEL

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 16, 26

GRAY MICHAEL

Direct

Sell$4.7K
Sep 16, 26

Ambrose Allison

Direct

Sell$2.7K
Sep 16, 26

Deykin Aaron

Direct

Sell$4.9K
Sep 16, 26

Sutherland Everett Rand

Direct

Sell$11.5K
Sep 16, 26

Houghton Adam

Direct

Sell$3.8K
Jun 16, 26

GRAY MICHAEL

Direct

Sell$5.2K
Jun 16, 26

Sutherland Everett Rand

Direct

Sell$12.8K
Jun 16, 26

Houghton Adam

Direct

Sell$4.3K
Jun 16, 26

Deykin Aaron

Direct

Sell$5.5K
Jun 16, 26

Ambrose Allison

Direct

Sell$2.9K

1–10 of 15

Summary

Insiders reported 0 buys worth $0.00 and 15 sells worth $104,796.49 over the last 12 months. That adds up to net selling of $104,796.49. GRAY MICHAEL was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+33.0%
+76.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +33.0% over three years. Forward estimates point to Revenue at +76.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Upstream Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about UPB's management, answered from reported figures.

Who manages UPB?

Upstream Bio, Inc. (UPB) lists 10 active executives. The top listed executive is Fang Xie, Vice President & Head of Biometrics.

Are UPB insiders buying or selling?

Recent insider activity shows net buying of $77.06M.